Experiences in Fragment-Based Lead Discovery
- 1 January 2011
- book chapter
- Published by Elsevier BV in Methods in Enzymology
- Vol. 493, 509-531
- https://doi.org/10.1016/b978-0-12-381274-2.00020-0
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular ChaperoneJournal of Medicinal Chemistry, 2009
- Lessons for fragment library design: analysis of output from multiple screening campaignsJournal of Computer-Aided Molecular Design, 2009
- From fragment to clinical candidate—a historical perspectiveDrug Discovery Today, 2009
- Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agentProceedings of the National Academy of Sciences of the United States of America, 2009
- Recent Developments in Fragment-Based Drug DiscoveryJournal of Medicinal Chemistry, 2008
- Stoichiometry and Physical Chemistry of Promiscuous Aggregate-Based InhibitorsJournal of the American Chemical Society, 2008
- 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of CancerJournal of Medicinal Chemistry, 2007
- Drug–target residence time and its implications for lead optimizationNature Reviews Drug Discovery, 2006
- A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug designNature Biotechnology, 2005
- Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein TargetsJournal of Chemical Information and Computer Sciences, 2004